Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06476808 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 240
- Enrollment target
- 16
- Study locations
NCT06476808: Recruiting Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC), sponsored by Bristol-Myers Squibb.
NCT06476808 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 240 participants, below the 281-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (15% lower). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06476808, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 240 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Conditions Studied
Interventions
- DRUG BMS-986463
Study Locations (16)
Other
- Local Institution - 0036 - Borddeaux Cedex
- Local Institution - 0035 - Lyon
- Local Institution - 0033 - Milan
- Local Institution - 0041 - Avda.Pio XII 36,
- Local Institution - 0042 - Barcelona
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
Quebec
- Centre Hospitalier de l'Université de Montréal - Montreal
- Jewish General Hospital - Montreal
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Ohio
- Local Institution - 0045 - Columbus
Texas
- Local Institution - 0046 - Dallas
British Columbia
- BC Cancer Vancouver - Vancouver
Ontario
- Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-09-06 |
| Est. Completion | 2028-12-19 |
| Phase | Phase 1 |
What NCT06476808 shows while recruiting
NCT06476808 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 281-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (15% lower).
The record links to 3 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which BMS-986463 is the first listed.
NCT06476808 lists 16 locations in 10 states (Other, California, Quebec).
Frequently Asked Questions
What is clinical trial NCT06476808 about?
NCT06476808 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.". The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
What is the current status of trial NCT06476808?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-09-06. Estimated completion is 2028-12-19.
What conditions does trial NCT06476808 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC).
What interventions are being tested in trial NCT06476808?
The interventions under investigation include: BMS-986463 (DRUG).
Who is sponsoring clinical trial NCT06476808?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06476808 being conducted?
This trial has 16 study locations across California, New Jersey, Ohio, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06476808's enrollment target sits among peer trials
240 26th of 59 higher than 33 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI